Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to “Hold” at StockNews.com

StockNews.com upgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a sell rating to a hold rating in a report published on Monday.

Oramed Pharmaceuticals Stock Down 1.3 %

NASDAQ ORMP opened at $2.36 on Monday. The company has a market capitalization of $95.14 million, a price-to-earnings ratio of 21.45 and a beta of 1.67. Oramed Pharmaceuticals has a twelve month low of $2.00 and a twelve month high of $3.67. The stock has a fifty day simple moving average of $2.38 and a 200 day simple moving average of $2.41.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ORMP. Dimensional Fund Advisors LP boosted its position in shares of Oramed Pharmaceuticals by 52.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 10,774 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Oramed Pharmaceuticals by 89.0% in the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after buying an additional 108,700 shares during the period. XTX Topco Ltd bought a new position in shares of Oramed Pharmaceuticals during the 2nd quarter worth approximately $40,000. Murchinson Ltd. grew its position in shares of Oramed Pharmaceuticals by 23.2% during the 2nd quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock worth $4,369,000 after buying an additional 320,495 shares during the period. Finally, BML Capital Management LLC increased its stake in shares of Oramed Pharmaceuticals by 62.1% in the 3rd quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock valued at $5,334,000 after acquiring an additional 837,153 shares in the last quarter. Institutional investors and hedge funds own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.